The Innovation Paradox in Emerging Pharmaceutical Markets: Barriers and Opportunities for Sustainable Development

Area of Science:

• Pharmaceutical sciences
• Drug development
• Emerging markets

Background:

• Emerging pharmaceutical markets (Brazil, India, China) show growth but focus on generics over innovation.
• Challenges include fragmented regulations, limited infrastructure, low R&D budgets, and API import reliance.
• R&D investment in emerging markets (≤5% revenue) lags behind established markets (20%), widening the innovation gap.

Purpose of the Study:

• To explore how advanced technologies can overcome barriers to drug innovation in emerging markets.
• To demonstrate the financial and operational benefits of adopting innovative tools for pharmaceutical companies.
• To assess the potential for these technologies to improve global competitiveness and access to medicines.

Main Methods:

• Review of challenges in emerging pharmaceutical markets.
• Analysis of advanced technologies: physiologically based pharmacokinetic (PBPK) modeling, artificial intelligence (AI), virtual bioequivalence studies.
• Case study on generic donepezil utilizing PBPK modeling.

Main Results:

• Physiologically based pharmacokinetic (PBPK) modeling, AI, and virtual bioequivalence studies streamline development and reduce costs.
• A case study showed PBPK modeling investment yielded 113.7% return (with clinical studies) to 1,120% (with biowaiver).
• Adoption of advanced tools enables faster market entry, scalability, and alignment with global regulatory trends.

Conclusions:

• Advanced technologies offer a pathway for emerging markets to bridge the innovation gap and enhance global competitiveness.
• Implementing tools like PBPK modeling improves resource efficiency, sustainability, and access to affordable medicines.
• Embracing technological innovation is crucial for emerging markets to achieve economic growth and leadership in the pharmaceutical sector.